reported a median PFS of 9.4 months and a 1‐year OS rate of 72.5% in 40 NSCLC patients treated with a combination of atezolizumab, bevacizumab, pemetrexed, and carboplatin after EGFR‐TKI treatment failure [24]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.